Schering: MS drug reduces onset by 50%
Schering has unveiled Phase III trial data that shows its multiple sclerosis drug Betaferon reduced the risk of developing the disease among early-stage patients by 50 percent. Schering said it will seek approval for a wider use of the drug by expanding its label. That would help enhance sales of the drug, which hit $939 million last year. The data was presented at the European Committee for Treatment and Research in Multiple Sclerosis conference in Greece.
- read this story from AFX for more
Comments